BR112021020924A2 - Uso de um anticorpo anti-cd19 para tratar doença autoimune - Google Patents
Uso de um anticorpo anti-cd19 para tratar doença autoimuneInfo
- Publication number
- BR112021020924A2 BR112021020924A2 BR112021020924A BR112021020924A BR112021020924A2 BR 112021020924 A2 BR112021020924 A2 BR 112021020924A2 BR 112021020924 A BR112021020924 A BR 112021020924A BR 112021020924 A BR112021020924 A BR 112021020924A BR 112021020924 A2 BR112021020924 A2 BR 112021020924A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- autoimmune disease
- treat autoimmune
- treat
- vib551
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838093P | 2019-04-24 | 2019-04-24 | |
| US201962843096P | 2019-05-03 | 2019-05-03 | |
| US201962858495P | 2019-06-07 | 2019-06-07 | |
| PCT/US2020/029613 WO2020219743A2 (en) | 2019-04-24 | 2020-04-23 | Use of an anti-cd19 antibody to treat autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020924A2 true BR112021020924A2 (pt) | 2022-04-19 |
Family
ID=72940915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020924A BR112021020924A2 (pt) | 2019-04-24 | 2020-04-23 | Uso de um anticorpo anti-cd19 para tratar doença autoimune |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220204617A1 (https=) |
| EP (1) | EP3959241A4 (https=) |
| JP (2) | JP7779738B2 (https=) |
| KR (1) | KR20220004113A (https=) |
| CN (1) | CN113939532A (https=) |
| AU (1) | AU2020263418A1 (https=) |
| BR (1) | BR112021020924A2 (https=) |
| CA (1) | CA3136487A1 (https=) |
| IL (1) | IL287385A (https=) |
| MX (1) | MX2021012870A (https=) |
| SG (1) | SG11202111429UA (https=) |
| WO (1) | WO2020219743A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3809260A1 (de) * | 2019-10-18 | 2021-04-21 | Siemens Healthcare GmbH | System und verfahren zur administration von bildgebenden geräten |
| WO2022006283A2 (en) * | 2020-06-30 | 2022-01-06 | Viela Bio, Inc. | Methods of treating neuromyelitis optica spectrum disorder |
| AU2021368769A1 (en) * | 2020-10-29 | 2023-06-08 | Viela Bio, Inc. | Use of an anti-cd19 antibody to treat autoimmune disease |
| IL308296A (en) * | 2021-05-07 | 2024-01-01 | Viela Bio Inc | Use of anti-CD19 antibody to treat myasthenia gravis |
| CN119604305A (zh) | 2022-07-27 | 2025-03-11 | 维埃拉生物股份有限公司 | 伊奈利珠单抗及使用其用于持续b细胞耗竭的方法 |
| WO2024155810A1 (en) * | 2023-01-20 | 2024-07-25 | Viela Bio, Inc. | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101534859B (zh) * | 2006-09-08 | 2017-06-09 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| RU2495882C2 (ru) * | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| MX2014010987A (es) * | 2012-03-12 | 2015-03-03 | Medimmune Llc | Tratamiento de esclerosis multiple con anticuerpo anti-cd19. |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
-
2020
- 2020-04-23 AU AU2020263418A patent/AU2020263418A1/en active Pending
- 2020-04-23 JP JP2021563213A patent/JP7779738B2/ja active Active
- 2020-04-23 CA CA3136487A patent/CA3136487A1/en active Pending
- 2020-04-23 WO PCT/US2020/029613 patent/WO2020219743A2/en not_active Ceased
- 2020-04-23 US US17/606,306 patent/US20220204617A1/en active Pending
- 2020-04-23 KR KR1020217038068A patent/KR20220004113A/ko active Pending
- 2020-04-23 EP EP20794203.8A patent/EP3959241A4/en active Pending
- 2020-04-23 CN CN202080030819.6A patent/CN113939532A/zh active Pending
- 2020-04-23 MX MX2021012870A patent/MX2021012870A/es unknown
- 2020-04-23 BR BR112021020924A patent/BR112021020924A2/pt unknown
- 2020-04-23 SG SG11202111429UA patent/SG11202111429UA/en unknown
-
2021
- 2021-10-19 IL IL287385A patent/IL287385A/en unknown
-
2025
- 2025-07-17 JP JP2025120173A patent/JP2025157413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020219743A3 (en) | 2020-12-10 |
| JP2025157413A (ja) | 2025-10-15 |
| CA3136487A1 (en) | 2020-10-29 |
| SG11202111429UA (en) | 2021-11-29 |
| US20220204617A1 (en) | 2022-06-30 |
| EP3959241A2 (en) | 2022-03-02 |
| WO2020219743A2 (en) | 2020-10-29 |
| IL287385A (en) | 2021-12-01 |
| CN113939532A (zh) | 2022-01-14 |
| KR20220004113A (ko) | 2022-01-11 |
| EP3959241A4 (en) | 2023-01-25 |
| JP2022529743A (ja) | 2022-06-23 |
| MX2021012870A (es) | 2022-01-18 |
| AU2020263418A1 (en) | 2021-11-11 |
| JP7779738B2 (ja) | 2025-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021020924A2 (pt) | Uso de um anticorpo anti-cd19 para tratar doença autoimune | |
| CR20220479A (es) | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap | |
| EA200970556A1 (ru) | Моноклональные антитела против angptl3 | |
| AR114112A1 (es) | Anticuerpos de glipicano 3 y conjugados de los mismos | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| UY38244A (es) | AGENTES ENLAZANTES DE PSMA y SUS USOS | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| CO2021000386A2 (es) | Anticuerpos humanizados contra psma | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| EA202192130A1 (ru) | Специфичные к ltbp-комплексу ингибиторы tgf и их применение | |
| EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
| BR112021011529A2 (pt) | Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| EP4490197A4 (en) | Humanized Anti-CD45 Antibodies | |
| AU2017255888A1 (en) | Humanized anti-BASIGIN antibodies and the use thereof | |
| AR120093A1 (es) | Anticuerpos anti-ceacam y usos de los mismos | |
| MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
| PH12022552725A1 (en) | Anti-ox40 antibody and uses thereof | |
| CO2022010204A2 (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| CR20210467A (es) | Tratamiento de cáncer con anticuerpos biespecíficos contra her2xcd3 en combinación con mab anti-her2 | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| MX2023004794A (es) | Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: VIELA BIO, INC. (US) |